

People

A sample of goings-on in and around the biotech and pharmaceutical industry.



Aravive has announced the promotion of **Gail McIntyre** (photo) to CSO. McIntyre has over 25 years of experience in the biopharma industry, having focused much of her time on moving compounds through lead optimization and preclinical development and onto the market. She joined Aravive in August 2016, most recently serving as senior vice president of research and development. Previously, she was a principal at IntelliDev Consulting and vice president of development for Meryx.

“Aravive continues to work towards its goal of bringing innovative therapies to patients in need, and I am thrilled to further strengthen our executive team with the promotion of Gail to chief scientific officer,” said Jay Shepard, president and CEO. “As a board-certified toxicologist, Gail brings extensive experience in preclinical development and has guided multiple therapies from discovery through approval. We are excited to continue leveraging her skills in this expanded role.”

Richard Brudnick has been appointed interim non-executive director of the board of InflaRx. He currently serves as chief business officer and head of strategy for Codiak BioSciences.

Singapore-based Tessa Therapeutics announced the appointment of 30-year industry veteran **Jeffrey H. Buchalter** as an independent director. Buchalter’s prior positions include chairman, president and CEO of Archimedes Pharma and chairman, president and CEO of Enzon Pharmaceuticals.

John J. Crowley has been appointed CFO of Fusion Pharmaceuticals. He brings over 20 years of global biotech financial and operational experience, most recently serving as executive vice president and CFO at Merus. Previously, he was corporate senior vice president, corporate controller and chief accounting officer at Charles River Laboratories and vice president, corporate controller and chief accounting officer at Ironwood Pharmaceuticals.

Swiss biopharma Novaremed has announced the appointment of **Nicholas Draeger** as CEO, succeeding founder **Eli Kaplan**, who will take a new role to support the company’s development of its lead asset and expansion of its drug pipeline. Draeger was most recently CEO of Nurevas International, which he cofounded in 2011. Previously, he served in healthcare portfolio management roles at BB Biotech and Adamant BioMedical Investments.

ReViral has announced the appointment of **Seth Hetherington** as chief medical officer.

Hetherington brings more than three decades of clinical, regulatory and industry experience in developing treatments for clinically important viral infections. He joins ReViral from Genocera Biosciences, where he had served as chief medical officer since 2012.


Enzyvant has named **Rachelle Jacques** as CEO. She joins Enzyvant from Alexion, where she most recently served as senior vice president and global franchise head of complement. Previously, she was vice president of US hematology marketing at Shire and Baxalta and vice president, business operations for the global bioscience business unit at Baxter International.

Life Biosciences has announced the appointment of **Mehmood Khan** as CEO and member of its board of directors. Khan was most recently vice chairman and CSO of beverage and snack giant PepsiCo. Prior to joining PepsiCo, he served as president of the Takeda Global Research & Development Center.

Ascletois Pharma has named **Zhengqing Li** as chief medical officer and president of R&D Greater China. Li joins Ascletois from MSD China, where he served as global vice president and general manager of its R&D center in China since 2011.

Antony Loebel has been named president and CEO of Sunovion Pharmaceuticals. Currently executive vice president, chief medical officer and head of global clinical development for Sumitomo Dainippon Pharma Group, Loebel will succeed **Nobuhiko Tamura**, who has served as Sunovion’s executive leader since 2014.

Immunomedics has announced that **Michael Pehl** has stepped down from the role of president, CEO and member of the board of directors for personal reasons, and interim CFO **Usama Malik** has been appointed CFO. In addition, the company has named **Charles Baum**, president and CEO of Mirati Therapeutics, to the Immunomedics board.



Cerevel Therapeutics has appointed **Raymond Sanchez** (photo) as chief medical officer. Sanchez joins Cerevel from

Otsuka Pharmaceutical, where he most recently served as senior vice president, global clinical development. He was also appointed chief medical officer of Avanir Pharmaceuticals during the last half of his 11-year tenure at Otsuka.

Victoria Smith has been named CSO of Amphivena Therapeutics. She joins Amphivena from Gilead, where she led the biologics and target biology group. Previously, she was Arresto Biosciences’ vice president of research and preclinical development. In addition, Amphivena has announced that **Peter Van Vlasselaer**, most recently the founder, president and CEO of ARMO Biosciences, has joined its board of directors as executive chairman.



Oncology startup Notable Labs has expanded its management team with the addition of **Hiroomi Tada** (photo) as chief medical officer

and **Lloyd Mackenzie** as chief development officer. Tada joins Notable from Incyte, where he was most recently vice president, targeted therapies, translational sciences. Mackenzie has 24 years of industry experience, most recently serving as COO and vice president, R&D operations at Aquinox Pharmaceuticals.

Published online: 2 April 2019
<https://doi.org/10.1038/s41587-019-0092-4>